Document is current
Any future updates will be listed below
-
Authors
Li, Dan
Li, Jianying
Johann, Donald J. Jr
Butler, Daniel
Chen, Guangchun
Foox, Jonathan
Gong, Binsheng
Jones, Wendell
Kreil, David P.
Kusko, Rebecca
Łabaj, Paweł P.
Lucas, Anne Bergstrom
Mason, Christopher E.
Mozsary, Christopher
Novoradovskaya, Natalia
Pabón-Peña, Carlos
Pan, Bohu
Richmond, Todd A.
Maestro, Roberta
Ebrahim Sahraeian, Sayed Mohammad
Scherer, Andreas
Tilgner, Hagen U.
Willey, James C.
Bushel, Pierre R.
Xu, Joshua
-
Funding
Funding for this research was provided by:
George Isaac Family Cancer Research Fund
- License Information
-
More Information
Article History
Received: 8 November 2024
Accepted: 3 June 2025
First Online: 13 June 2025
Competing interests
: The authors declare the following potential competing financial interests: Author N.N., A.B.L., and C.P.P. were employees of Agilent Technologies, Inc., but declares no non-financial competing interests. Authors D.L., J.L., D.J.J.Jr., D.B., G.C., J.F., B.G., W.J., D.P.K, R.K., P.L., C.E.M., C.M., B.P., T.A.R., R.M., S.M.E.S., A.S., H.U.T., J.C.W., P.R.B., and J.X. declare no financial or non-financial competing interests. UHRR is a commercial product of Agilent, and sample A DNA is a potential product of Agilent Technologies, Inc.
